Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26104585 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Tihomir Zh Todorov und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, 5232 Villigen PSI, Switzerland. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Signal Transduction, Proteomics, Neural Cell Adhesion Molecule L1. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Swiss Cancer League, Mahari-Stiftung (Switzerland), Swiss Cancer Research Foundation.
Abstract (Originalsprache)
Quantitative phosphoproteomics enables the comprehensive analysis of signaling pathways driven by overexpressed cancer receptors, revealing the molecular mechanisms that underpin tumor progression and therapy resistance. The glycoprotein L1 cell adhesion molecule (L1CAM) is overexpressed in high-grade serous ovarian carcinoma (HGSOC) and plays a crucial role in carcinogenesis by regulating cancer stem cell properties. Here, CRISPR–Cas9-mediated knockout of L1CAM in ovarian cancer OVCAR8 and OVCAR4 cells significantly impaired anchor-independent growth in soft agar assays and reduced clonogenic survival following external beam irradiation. In vivo, L1CAM knockout decreased cancer stem cell frequency and significantly decreased tumorigenicity. To uncover L1CAM-regulated signaling networks, we employed quantitative phosphoproteomics and proteomics. Bioinformatics analyses and validation studies revealed L1CAM-associated pathways that contribute to radioresistance through DNA repair processes and mammalian target or rapamycin complex 1 (mTORC1)-mediated signaling. In conclusion, our study established a link between L1CAM-dependent tumorigenesis and radioresistance, both hallmarks of cancer stemness, with phosphorylation of key proteins involved in DNA damage response. This study further emphasizes the value of quantitative phosphoproteomics in cancer research, showcasing its ability to enhance understanding of cancer progression and therapy resistance.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Radiopharmaceutical Sciences, PSI Center for Life Sciences, 5232 Villigen PSI, Switzerland.
- Ovarian Cancer Research, Department of Biomedicine, University Hospital Basel, University of Basel, 4031 Basel, Switzerland.
- Department of Chemistry and Applied Biosciences, ETH Zurich, 8093 Zurich, Switzerland.
- Department of Gynecology and Gynecological Oncology, Hospital for Women, University Hospital Basel, 4031 Basel, Switzerland.
ORCID-Profile: Tihomir Zh Todorov, Francis Jacob, Roger Schibli, Martin Béhé, Jürgen Grünberg, Michal Grzmil
Förderung
- Swiss Cancer League
- Mahari-Stiftung (Switzerland)
- Swiss Cancer Research Foundation
Zitieren
APA
Todorov, T. Z., Coelho, R., Jacob, F., Heinzelmann-Schwarz, V., Schibli, R., Béhé, M., Grünberg, J., & Grzmil, M. (2025). Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26104585
Vancouver
Todorov TZ, Coelho R, Jacob F, Heinzelmann-Schwarz V, Schibli R, Béhé M, et al. Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26104585
BibTeX
@article{Todorov2025,
author = {Todorov, Tihomir Zh and Coelho, Ricardo and Jacob, Francis and Heinzelmann-Schwarz, Viola and Schibli, Roger and Béhé, Martin and Grünberg, Jürgen and Grzmil, Michal},
title = {Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26104585}
}
EUVIMED